Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating expenses:
Research and development expenses	$ 4,576,389	$ 6,803,900	$ 14,620,308	$ 18,035,762
General and administrative expenses	3,563,753	3,374,794	10,248,943	10,924,863
Total operating expenses	8,140,142	10,178,694	24,869,251	28,960,625
Loss from operations	(8,140,142)	(10,178,694)	(24,869,251)	(28,960,625)
Interest income (expenses), net
Interest income	281,109	666,770	992,582	2,010,874
Interest expense	(1,150,378)	(1,214,734)	(4,225,737)	(3,577,450)
Interest income (expenses), net	(869,269)	(547,964)	(3,233,155)	(1,566,576)
Loss before income taxes	(9,009,411)	(10,726,658)	(28,102,406)	(30,527,201)
Benefit from income taxes	0	0	1,169,820	869,169
Net loss	(9,009,411)	(10,726,658)	(26,932,586)	(29,658,032)
Comprehensive loss	$ (9,009,411)	$ (10,726,658)	$ (26,932,586)	$ (29,658,032)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.19)	$ (0.29)	$ (0.6)	$ (0.82)
Net loss per share, diluted (in dollars per share)	$ (0.19)	$ (0.29)	$ (0.6)	$ (0.82)
Weighted average common shares outstanding, basic (in shares)	46,869,531	36,806,592	44,648,508	36,107,900
Weighted average common shares outstanding, diluted (in shares)	46,869,531	36,806,592	44,648,508	36,107,900